Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Pancreatic Cancer: Immunotherapy combinations in metastatic PDAC
NCT03193190Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in pancreatic ductal adenocarcinoma (PDAC) (12 cohorts), sponsored by Roche. Primary endpoint: Objective Response Rate at 33.3 months. Started Jul 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03193190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193190.